{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:37:30Z","timestamp":1793619450963,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00198-023-06818-3","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T03:02:22Z","timestamp":1686884542000},"page":"1729-1737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan"],"prefix":"10.1007","volume":"34","author":[{"given":"Fang-Chun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwing-Chi","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5980-6960","authenticated-orcid":false,"given":"Yung-Chih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"6818_CR1","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/jbmr.2269","volume":"29","author":"NC Wright","year":"2014","unstructured":"Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 29:2520\u20132526","journal-title":"J Bone Miner Res"},{"key":"6818_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161435.GL","volume":"22","author":"PM Camacho","year":"2016","unstructured":"Camacho PM, Petak SM, Binkley N et al (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2016. Endocr Pract 22:1\u201342","journal-title":"Endocr Pract"},{"key":"6818_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4103\/njms.NJMS_236_20","volume":"13","author":"H Bansal","year":"2022","unstructured":"Bansal H (2022) Medication-related osteonecrosis of the jaw: An update. Natl J Maxillofac Surg 13:5\u201310","journal-title":"Natl J Maxillofac Surg"},{"key":"6818_CR4","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O\u2019Ryan F, American Association of O, Maxillofacial S (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update. J Oral Maxillofac Surg 72:1938\u20131956","journal-title":"J Oral Maxillofac Surg"},{"key":"6818_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3\u201323","journal-title":"J Bone Miner Res"},{"key":"6818_CR6","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115\u20131117","journal-title":"J Oral Maxillofac Surg"},{"key":"6818_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"SL Ruggiero","year":"2004","unstructured":"Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527\u2013534","journal-title":"J Oral Maxillofac Surg"},{"key":"6818_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","volume":"65","author":"S Maxillofacial","year":"2007","unstructured":"Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws AAoO, Maxillofacial S (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369\u2013376","journal-title":"J Oral Maxillofac Surg"},{"key":"6818_CR9","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1093\/annonc\/mdn653","volume":"19","author":"S Greuter","year":"2008","unstructured":"Greuter S, Schmid F, Ruhstaller T, Thuerlimann B (2008) Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol 19:2091\u20132092","journal-title":"Ann Oncol"},{"key":"6818_CR10","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.bone.2012.08.115","volume":"51","author":"T Yamazaki","year":"2012","unstructured":"Yamazaki T, Yamori M, Yamamoto K, Saito K, Asai K, Sumi E, Goto K, Takahashi K, Nakayama T, Bessho K (2012) Risk of osteomyelitis of the jaw induced by oral bisphosphonates in patients taking medications for osteoporosis: a hospital-based cohort study in Japan. Bone 51:882\u2013887","journal-title":"Bone"},{"key":"6818_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0022034510397196","volume":"90","author":"A Barasch","year":"2011","unstructured":"Barasch A, Cunha-Cruz J, Curro FA et al (2011) Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res 90:439\u2013444","journal-title":"J Dent Res"},{"key":"6818_CR12","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/COC.0b013e3182155fcb","volume":"35","author":"V Thumbigere-Math","year":"2012","unstructured":"Thumbigere-Math V, Tu L, Huckabay S, Dudek AZ, Lunos S, Basi DL, Hughes PJ, Leach JW, Swenson KK, Gopalakrishnan R (2012) A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. Am J Clin Oncol 35:386\u2013392","journal-title":"Am J Clin Oncol"},{"key":"6818_CR13","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.joms.2013.02.016","volume":"71","author":"C Tsao","year":"2013","unstructured":"Tsao C, Darby I, Ebeling PR, Walsh K, O\u2019Brien-Simpson N, Reynolds E, Borromeo G (2013) Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg 71:1360\u20131366","journal-title":"J Oral Maxillofac Surg"},{"key":"6818_CR14","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341\u20131347","journal-title":"Ann Oncol"},{"key":"6818_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","volume":"122","author":"V Guarneri","year":"2010","unstructured":"Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122:181\u2013188","journal-title":"Breast Cancer Res Treat"},{"key":"6818_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.afos.2017.03.001","volume":"3","author":"A Taguchi","year":"2017","unstructured":"Taguchi A, Shiraki M, Morrison A, Khan AA (2017) Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries. Osteoporos Sarcopenia 3:64\u201374","journal-title":"Osteoporos Sarcopenia"},{"key":"6818_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","volume":"68","author":"JC Lo","year":"2010","unstructured":"Lo JC, O\u2019Ryan FS, Gordon NP et al (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68:243\u2013253","journal-title":"J Oral Maxillofac Surg"},{"key":"6818_CR18","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.14219\/jada.archive.2010.0082","volume":"141","author":"JT Grbic","year":"2010","unstructured":"Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, Bucci-Rechtweg C, Su G (2010) The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc 141:1365\u20131370","journal-title":"J Am Dent Assoc"},{"key":"6818_CR19","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/jbmr.2442","volume":"30","author":"DM Black","year":"2015","unstructured":"Black DM, Reid IR, Cauley JA et al (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 30:934\u2013944","journal-title":"J Bone Miner Res"},{"key":"6818_CR20","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"6818_CR21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/jbmr.1479","volume":"27","author":"S Papapoulos","year":"2012","unstructured":"Papapoulos S, Chapurlat R, Libanati C et al (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694\u2013701","journal-title":"J Bone Miner Res"},{"key":"6818_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00198-012-2052-4","volume":"24","author":"MR McClung","year":"2013","unstructured":"McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, Ding B, Rockabrand E, Wagman RB, Miller PD (2013) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 24:227\u2013235","journal-title":"Osteoporos Int"},{"key":"6818_CR23","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","volume":"26","author":"S Papapoulos","year":"2015","unstructured":"Papapoulos S, Lippuner K, Roux C et al (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 26:2773\u20132783","journal-title":"Osteoporos Int"},{"key":"6818_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.afos.2016.03.003","volume":"2","author":"B Benjamin","year":"2016","unstructured":"Benjamin B, Benjamin MA, Swe M, Sugathan S (2016) Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis. Osteoporos Sarcopenia 2:77\u201381","journal-title":"Osteoporos Sarcopenia"},{"key":"6818_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.bonr.2017.11.002","volume":"7","author":"T Sone","year":"2017","unstructured":"Sone T, Kon N, Gaither KW, Okubo N, Osakabe T, Nakayama Y, Fukunaga M, Ito M, Nakamura T (2017) Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis. Bone Rep 7:164\u2013171","journal-title":"Bone Rep"},{"key":"6818_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.afos.2017.01.002","volume":"3","author":"MR McClung","year":"2017","unstructured":"McClung MR (2017) Denosumab for the treatment of osteoporosis. Osteoporos Sarcopenia 3:8\u201317","journal-title":"Osteoporos Sarcopenia"},{"key":"6818_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6818_CR28","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joms.2009.10.010","volume":"68","author":"TL Aghaloo","year":"2010","unstructured":"Aghaloo TL, Felsenfeld AL, Tetradis S (2010) Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg 68:959\u2013963","journal-title":"J Oral Maxillofac Surg"},{"key":"6818_CR29","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/ijcp.12022","volume":"66","author":"DA Hanley","year":"2012","unstructured":"Hanley DA, Adachi JD, Bell A, Brown V (2012) Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 66:1139\u20131146","journal-title":"Int J Clin Pract"},{"key":"6818_CR30","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1016\/j.ajpath.2014.07.010","volume":"184","author":"DW Williams","year":"2014","unstructured":"Williams DW, Lee C, Kim T et al (2014) Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-kappaB ligand antibody in mice. Am J Pathol 184:3084\u20133093","journal-title":"Am J Pathol"},{"key":"6818_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","volume":"59","author":"RM Zebaze","year":"2014","unstructured":"Zebaze RM, Libanati C, Austin M et al (2014) Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone 59:173\u2013179","journal-title":"Bone"},{"key":"6818_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.bjoms.2014.01.021","volume":"52","author":"O Ristow","year":"2014","unstructured":"Ristow O, Gerngross C, Schwaiger M, Hohlweg-Majert B, Kehl V, Jansen H, Hahnefeld L, Koerdt S, Otto S, Pautke C (2014) Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates. Br J Oral Maxillofac Surg 52:308\u2013313","journal-title":"Br J Oral Maxillofac Surg"},{"key":"6818_CR33","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT et al (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082\u20133092","journal-title":"Eur J Cancer"},{"key":"6818_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","volume":"19","author":"WX Qi","year":"2014","unstructured":"Qi WX, Tang LN, He AN, Yao Y, Shen Z (2014) Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol 19:403\u2013410","journal-title":"Int J Clin Oncol"},{"key":"6818_CR35","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","volume":"7","author":"GV Scagliotti","year":"2012","unstructured":"Scagliotti GV, Hirsh V, Siena S et al (2012) Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 7:1823\u20131829","journal-title":"J Thorac Oncol"},{"key":"6818_CR36","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125\u20131132","journal-title":"J Clin Oncol"},{"key":"6818_CR37","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. The Lancet 377:813\u2013822","journal-title":"The Lancet"},{"key":"6818_CR38","doi-asserted-by":"publisher","first-page":"e0120756","DOI":"10.1371\/journal.pone.0120756","volume":"10","author":"YF Huang","year":"2015","unstructured":"Huang YF, Chang CT, Muo CH, Tsai CH, Shen YF, Wu CZ (2015) Impact of bisphosphonate-related osteonecrosis of the jaw on osteoporotic patients after dental extraction: a population-based cohort study. PLoS ONE 10:e0120756","journal-title":"PLoS ONE"},{"key":"6818_CR39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","volume":"35","author":"T Yoneda","year":"2017","unstructured":"Yoneda T, Hagino H, Sugimoto T et al (2017) Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 35:6\u201319","journal-title":"J Bone Miner Metab"},{"key":"6818_CR40","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00198-009-1024-9","volume":"21","author":"JW Hong","year":"2010","unstructured":"Hong JW, Nam W, Cha IH, Chung SW, Choi HS, Kim KM, Kim KJ, Rhee Y, Lim SK (2010) Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia. Osteoporos Int 21:847\u2013853","journal-title":"Osteoporos Int"},{"key":"6818_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5125\/jkaoms.2013.39.1.9","volume":"39","author":"JK Lee","year":"2013","unstructured":"Lee JK, Kim KW, Choi JY et al (2013) Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report. J Korean Assoc Oral Maxillofac Surg 39:9\u201313","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"key":"6818_CR42","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00198-014-2624-6","volume":"25","author":"TC Lin","year":"2014","unstructured":"Lin TC, Yang CY, Kao Yang YH, Lin SJ (2014) Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population. Osteoporos Int 25:1503\u20131511","journal-title":"Osteoporos Int"},{"key":"6818_CR43","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1210\/jc.2013-4119","volume":"99","author":"WY Chiu","year":"2014","unstructured":"Chiu WY, Chien JY, Yang WS, Juang JM, Lee JJ, Tsai KS (2014) The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. J Clin Endocrinol Metab 99:2729\u20132735","journal-title":"J Clin Endocrinol Metab"},{"key":"6818_CR44","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bj.2017.08.002","volume":"40","author":"MS Tsai","year":"2017","unstructured":"Tsai MS, Lin MH, Lee CP, Yang YH, Chen WC, Chang GH, Tsai YT, Chen PC, Tsai YH (2017) Chang Gung Research Database: a multi-institutional database consisting of original medical records. Biomed J 40:263\u2013269","journal-title":"Biomed J"},{"key":"6818_CR45","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/pds.5208","volume":"30","author":"SC Shao","year":"2021","unstructured":"Shao SC, Lai EC, Huang TH, Hung MJ, Tsai MS, Yang YH, Chan YY (2021) The Chang Gung Research Database: multi-institutional real-world data source for traditional Chinese medicine in Taiwan. Pharmacoepidemiol Drug Saf 30:652\u2013660","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6818_CR46","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE et al (2019) Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline. J Clin Oncol 37:2270\u20132290","journal-title":"J Clin Oncol"},{"key":"6818_CR47","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1210\/jc.2013-1597","volume":"98","author":"HG Bone","year":"2013","unstructured":"Bone HG, Chapurlat R, Brandi ML et al (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98:4483\u20134492","journal-title":"J Clin Endocrinol Metab"},{"key":"6818_CR48","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00198-012-2042-6","volume":"24","author":"DH Solomon","year":"2013","unstructured":"Solomon DH, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N (2013) Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int 24:237\u2013244","journal-title":"Osteoporos Int"},{"key":"6818_CR49","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg 80:920\u2013943","journal-title":"J Oral Maxillofac Surg"},{"key":"6818_CR50","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.joms.2018.05.025","volume":"76","author":"D Hadaya","year":"2018","unstructured":"Hadaya D, Soundia A, Freymiller E, Grogan T, Elashoff D, Tetradis S, Aghaloo TL (2018) Nonsurgical management of medication-related osteonecrosis of the jaws using local wound care. J Oral Maxillofac Surg 76:2332\u20132339","journal-title":"J Oral Maxillofac Surg"},{"key":"6818_CR51","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.oooo.2012.05.017","volume":"115","author":"AL Watters","year":"2013","unstructured":"Watters AL, Hansen HJ, Williams T, Chou JF, Riedel E, Halpern J, Tunick S, Bohle G, Huryn JM, Estilo CL (2013) Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients. Oral Surg Oral Med Oral Pathol Oral Radiol 115:192\u2013200","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"6818_CR52","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jcms.2018.12.014","volume":"47","author":"O Ristow","year":"2019","unstructured":"Ristow O, Ruckschloss T, Muller M, Berger M, Kargus S, Pautke C, Engel M, Hoffmann J, Freudlsperger C (2019) Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study. J Craniomaxillofac Surg 47:491\u2013499","journal-title":"J Craniomaxillofac Surg"},{"key":"6818_CR53","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.joms.2013.12.007","volume":"72","author":"ER Carlson","year":"2014","unstructured":"Carlson ER (2014) Management of antiresorptive osteonecrosis of the jaws with primary surgical resection. J Oral Maxillofac Surg 72:655\u2013657","journal-title":"J Oral Maxillofac Surg"},{"key":"6818_CR54","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ijom.2009.11.014","volume":"39","author":"RA Williamson","year":"2010","unstructured":"Williamson RA (2010) Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg 39:251\u2013255","journal-title":"Int J Oral Maxillofac Surg"},{"key":"6818_CR55","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.tripleo.2010.04.015","volume":"111","author":"F Wilde","year":"2011","unstructured":"Wilde F, Heufelder M, Winter K, Hendricks J, Frerich B, Schramm A, Hemprich A (2011) The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111:153\u2013163","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"6818_CR56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.oooo.2019.08.018","volume":"129","author":"A Yuan","year":"2020","unstructured":"Yuan A, Munz A, Reinert S, Hoefert S (2020) Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases. Oral Surg Oral Med Oral Pathol Oral Radiol 129:133\u2013140","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"6818_CR57","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00774-021-01223-4","volume":"39","author":"K Aoki","year":"2021","unstructured":"Aoki K, Matsunaga S, Ito S, Shibahara T, Nomura T, Matsuzaki H, Abe S, Yamaguchi A (2021) Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis. J Bone Miner Metab 39:737\u2013747","journal-title":"J Bone Miner Metab"},{"key":"6818_CR58","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1259\/dmfr\/27458726","volume":"35","author":"S Chiandussi","year":"2006","unstructured":"Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova MA, Di Lenarda R (2006) Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol 35:236\u2013243","journal-title":"Dentomaxillofac Radiol"},{"key":"6818_CR59","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.oooo.2019.09.010","volume":"129","author":"SEC Pichardo","year":"2020","unstructured":"Pichardo SEC, Broek FWT, Fiocco M, Appelman-Dijkstra NM, van Merkesteyn JPR (2020) A comparison of the cone beam computed tomography findings in medication-related osteonecrosis of the jaws related to denosumab versus bisphosphonates: an observational pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol 129:411\u2013417","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06818-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-023-06818-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06818-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T04:03:35Z","timestamp":1695182615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-023-06818-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["6818"],"URL":"https:\/\/doi.org\/10.1007\/s00198-023-06818-3","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"assertion":[{"value":"26 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}